Panpan Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Panpan Ma has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Bo Xiao
Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications Qiubing Chen
Education Ministry Key Laboratory on Luminescence and Real-Time Analysis, Faculty of Materials and Energy, Southwest University, Chongqing 400715, PR China; State Key Laboratory of Silkworm Genome Biology, Southwest University, Beibei, Chongqing 400715, PR China
3 shared publications- Yohann Corvis
Université Paris Cité, CNRS, INSERM Unité De Technologies Chimiques Et Biologiques pour La Santé (UTCBS) Paris‐75006 France
3 shared publications Charlotte Izabelle
Université Paris Cité, UAR3612 CNRS, US25 INSERM, Cellular and Molecular Imaging Facility, 75006 Paris, France
2 shared publicationsDidier Merlin
Institute for Biomedical Science, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta 30302, USA; Atlanta Veterans Affairs Medical Center, Decatur 30033, USA
2 shared publicationsJohanne Seguin
Université Paris Cité, CNRS, INSERM, UTCBS Lab, 75006 Paris, France
2 shared publications
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Elaboration of pharmaceutical interest nanosized crystals for bioavailability improvement of drugs
Élaboration de cristaux nanométriques d'intérêt pharmaceutique pour l'amélioration de la biodisponibilité des médicaments: Dans cette étude, des suspensions nanocristallines (NC) de fisétine et de curcumine et une combinaison d'étoposide (ETO) et de prednisolone (PRD) ont été développées pour des applications potentielles en nanomédecine. Les NC ont démontré d'excellentes caractéristiques, notamment une faible polydispersité, une bonne stabilité colloïdale et des propriétés de libération durable. Le protocole optimisé a permis la production à haut rendement de nanosuspensions à l'échelle du nanomètre, avec une stabilité pendant de longues périodes lorsqu'elles sont stockées dans des conditions appropriées. En particulier, les expériences de libération de médicaments ont confirmé le profil de libération prolongée de l'ingrédient pharmaceutique actif (API) à partir des NC, suggérant leur potentiel pour l'optimisation des fréquences d'administration et l'amélioration de l'observance des patients dans le traitement de diverses pathologies. Des évaluations in vitro utilisant des lignées de cellules tumorales murines et endothéliales humaines ont révélé que les CN présentaient une efficacité thérapeutique comparable à celle des préparations d'IPA libres. Parallèlement, l'étude s'est également concentrée sur le développement de cocristaux d'ETO et de PRD sous forme de nanocristaux combinés. Ces nanocristaux ETO/PRD ont été optimisés en utilisant le poloxamère P407 comme agent stabilisateur, ce qui a permis d'obtenir des nanosuspensions présentant des propriétés souhaitables telles que la taille moyenne, un faible indice de polydispersité et le potentiel zêta. Les NC ETO/PRD ont présenté une stabilité prolongée et une cinétique de libération similaire pour les deux ingrédients pharmaceutiques actifs. Les expériences de cytotoxicité ont notamment montré que les CN ETO/PRD présentaient de fortes activités anticancéreuses par rapport aux CN ETO ou aux formulations d'ETO libre. La combinaison de l'ETO et de la PRD dans les NC a également renforcé leurs propriétés antiangiogéniques, comme l'ont montré les essais de formation de tubes capillaires et les essais de cicatrisation par égratignure. En outre, les NC mixtes ont conservé leur efficacité dans l'inhibition du VEGF (facteur de croissance de l'endothélium vasculaire), comme l'ont démontré les essais immuno-absorbants ELISA du VEGF. Dans l'ensemble, ce travail de doctorat comprend la formulation de suspensions de nanocristaux anticancéreux, anti-angiogéniques et anti-inflammatoires en utilisant une approche de précipitation de solvant/antisolvant, la caractérisation structurelle, les études de dissolution, les études in vitro, soulignant les avantages des systèmes innovants d'administration de médicaments. Ces résultats offrent des perspectives prometteuses pour l'application de nanocristaux simples de fisétine et de curcumine et de nanocristaux mixtes combinés d'ETO et de PRD en nanomédecine et en chimiothérapie. Les suspensions nanocristallines ont présenté des caractéristiques favorables, une efficacité thérapeutique améliorée et des effets anti-angiogéniques renforcés dans des expériences in vitro, ce qui suggère leur potentiel en tant que nouvelles stratégies pour le traitement des tumeurs solides et l'amélioration des résultats pour les patients.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Elaboration of pharmaceutical interest nanosized crystals for bioavailability improvement of drugs
Élaboration de cristaux nanométriques d'intérêt pharmaceutique pour l'amélioration de la biodisponibilité des médicaments: Dans cette étude, des suspensions nanocristallines (NC) de fisétine et de curcumine et une combinaison d'étoposide (ETO) et de prednisolone (PRD) ont été développées pour des applications potentielles en nanomédecine. Les NC ont démontré d'excellentes caractéristiques, notamment une faible polydispersité, une bonne stabilité colloïdale et des propriétés de libération durable. Le protocole optimisé a permis la production à haut rendement de nanosuspensions à l'échelle du nanomètre, avec une stabilité pendant de longues périodes lorsqu'elles sont stockées dans des conditions appropriées. En particulier, les expériences de libération de médicaments ont confirmé le profil de libération prolongée de l'ingrédient pharmaceutique actif (API) à partir des NC, suggérant leur potentiel pour l'optimisation des fréquences d'administration et l'amélioration de l'observance des patients dans le traitement de diverses pathologies. Des évaluations in vitro utilisant des lignées de cellules tumorales murines et endothéliales humaines ont révélé que les CN présentaient une efficacité thérapeutique comparable à celle des préparations d'IPA libres. Parallèlement, l'étude s'est également concentrée sur le développement de cocristaux d'ETO et de PRD sous forme de nanocristaux combinés. Ces nanocristaux ETO/PRD ont été optimisés en utilisant le poloxamère P407 comme agent stabilisateur, ce qui a permis d'obtenir des nanosuspensions présentant des propriétés souhaitables telles que la taille moyenne, un faible indice de polydispersité et le potentiel zêta. Les NC ETO/PRD ont présenté une stabilité prolongée et une cinétique de libération similaire pour les deux ingrédients pharmaceutiques actifs. Les expériences de cytotoxicité ont notamment montré que les CN ETO/PRD présentaient de fortes activités anticancéreuses par rapport aux CN ETO ou aux formulations d'ETO libre. La combinaison de l'ETO et de la PRD dans les NC a également renforcé leurs propriétés antiangiogéniques, comme l'ont montré les essais de formation de tubes capillaires et les essais de cicatrisation par égratignure. En outre, les NC mixtes ont conservé leur efficacité dans l'inhibition du VEGF (facteur de croissance de l'endothélium vasculaire), comme l'ont démontré les essais immuno-absorbants ELISA du VEGF. Dans l'ensemble, ce travail de doctorat comprend la formulation de suspensions de nanocristaux anticancéreux, anti-angiogéniques et anti-inflammatoires en utilisant une approche de précipitation de solvant/antisolvant, la caractérisation structurelle, les études de dissolution, les études in vitro, soulignant les avantages des systèmes innovants d'administration de médicaments. Ces résultats offrent des perspectives prometteuses pour l'application de nanocristaux simples de fisétine et de curcumine et de nanocristaux mixtes combinés d'ETO et de PRD en nanomédecine et en chimiothérapie. Les suspensions nanocristallines ont présenté des caractéristiques favorables, une efficacité thérapeutique améliorée et des effets anti-angiogéniques renforcés dans des expériences in vitro, ce qui suggère leur potentiel en tant que nouvelles stratégies pour le traitement des tumeurs solides et l'amélioration des résultats pour les patients.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (20) , 5838-5849
Engineered Etoposide-Prednisolone Co-nanocrystals for Synergistic Antitumor Efficacy Enhancement
The present work consists in developing new organic crystalline nanomedicines, namely co-nanocrystals (co-NCs), that associate a chemotherapy with an anti-inflammatory active pharmaceutical ingredient (API) in their nanocrystalline forms. These mixed...
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (20) , 5838-5849
Open AccessEngineered Etoposide-Prednisolone Co-nanocrystals for Synergistic Antitumor Efficacy Enhancement
The present work consists in developing new organic crystalline nanomedicines, namely co-nanocrystals (co-NCs), that associate a chemotherapy with an anti-inflammatory active pharmaceutical ingredient (API) in their nanocrystalline forms. These mixed...
- Open Access
- 29 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1102
New Lidocaine-Based Pharmaceutical Cocrystals: Preparation, Characterization, and Influence of the Racemic vs. Enantiopure Coformer on the Physico-Chemical Properties
This study describes the preparation, characterization, and influence of the enantiopure vs. racemic coformer on the physico-chemical properties of a pharmaceutical cocrystal. For that purpose, two new 1:1 cocrystals, namely lidocaine:dl-menthol and lidocaine:d-menthol, were prepared. The menthol racemate-based cocrystal was evaluated by means of X-ray diffraction, infrared spectroscopy, Raman, thermal analysis, and solubility experiments. The results were exhaustively compared with the first menthol-based pharmaceutical cocrystal, i.e., lidocaine:l-menthol, discovered in our group 12 years ago. Furthermore, the stable lidocaine/dl-menthol phase diagram has been screened, thoroughly evaluated, and compared to the enantiopure phase diagram. Thus, it has been proven that the racemic vs. enantiopure coformer leads to increased solubility and improved dissolution of lidocaine due to the low stable form induced by menthol molecular disorder in the lidocaine:dl-menthol cocrystal. To date, the 1:1 lidocaine:dl-menthol cocrystal is the third menthol-based pharmaceutical cocrystal, after the 1:1 lidocaine:l-menthol and the 1:2 lopinavir:l-menthol cocrystals reported in 2010 and 2022, respectively. Overall, this study shows promising potential for designing new materials with both improved characteristics and functional properties in the fields of pharmaceutical sciences and crystal engineering.
- 29 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1102
Open AccessNew Lidocaine-Based Pharmaceutical Cocrystals: Preparation, Characterization, and Influence of the Racemic vs. Enantiopure Coformer on the Physico-Chemical Properties
This study describes the preparation, characterization, and influence of the enantiopure vs. racemic coformer on the physico-chemical properties of a pharmaceutical cocrystal. For that purpose, two new 1:1 cocrystals, namely lidocaine:dl-menthol and lidocaine:d-menthol, were prepared. The menthol racemate-based cocrystal was evaluated by means of X-ray diffraction, infrared spectroscopy, Raman, thermal analysis, and solubility experiments. The results were exhaustively compared with the first menthol-based pharmaceutical cocrystal, i.e., lidocaine:l-menthol, discovered in our group 12 years ago. Furthermore, the stable lidocaine/dl-menthol phase diagram has been screened, thoroughly evaluated, and compared to the enantiopure phase diagram. Thus, it has been proven that the racemic vs. enantiopure coformer leads to increased solubility and improved dissolution of lidocaine due to the low stable form induced by menthol molecular disorder in the lidocaine:dl-menthol cocrystal. To date, the 1:1 lidocaine:dl-menthol cocrystal is the third menthol-based pharmaceutical cocrystal, after the 1:1 lidocaine:l-menthol and the 1:2 lopinavir:l-menthol cocrystals reported in 2010 and 2022, respectively. Overall, this study shows promising potential for designing new materials with both improved characteristics and functional properties in the fields of pharmaceutical sciences and crystal engineering.
- Open Access
- 9 November 2022
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 4, 100138
Designing fisetin nanocrystals for enhanced in cellulo anti-angiogenic and anticancer efficacy
- 9 November 2022
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 4, 100138
Open AccessDesigning fisetin nanocrystals for enhanced in cellulo anti-angiogenic and anticancer efficacy
- Open Access
- 16 February 2021
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 8
Pluronic F127-Modified Electrospun Fibrous Meshes for Synergistic Combination Chemotherapy of Colon Cancer
Colon cancer ranks as the third most common malignancy in the world. Combination chemotherapy, resorting to electrospun fibrous technology, has been considered as a promising strategy to exert synergistic effects in colon cancer treatment. Herein, we manufactured various pluronic F127 (PF127)-modified electrospun fibrous meshes with different weight ratios of camptothecin (CPT) and curcumin (CUR). The fluorescence characterization of the obtained PF127-CPT-meshes, PF127-CUR-meshes, and PF127-CPT/CUR-meshes (2:1) showed that CPT and CUR were evenly distributed within individual fibers of these meshes. Drug release experiments revealed that both types of drugs could be released from fibrous meshes simultaneously and sustainably. Importantly, these meshes exhibited strong in vitro anti-colon cancer activities, compared with the control meshes without drugs. Moreover, the combination index values of the PF127-CPT/CUR-meshes (CPT/CUR weight ratio = 5:1, 3:1, or 2:1) were <0.5 after incubation for respective 24 and 36 h, indicating the synergistic anti-colon cancer effects of CPT and CUR in fibrous meshes. Collectively, these results demonstrate that PF127-CPT/CUR-meshes can be developed as an efficient implantable system for effective synergistic treatment of colon cancer.
- 16 February 2021
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 8
Open AccessPluronic F127-Modified Electrospun Fibrous Meshes for Synergistic Combination Chemotherapy of Colon Cancer
Colon cancer ranks as the third most common malignancy in the world. Combination chemotherapy, resorting to electrospun fibrous technology, has been considered as a promising strategy to exert synergistic effects in colon cancer treatment. Herein, we manufactured various pluronic F127 (PF127)-modified electrospun fibrous meshes with different weight ratios of camptothecin (CPT) and curcumin (CUR). The fluorescence characterization of the obtained PF127-CPT-meshes, PF127-CUR-meshes, and PF127-CPT/CUR-meshes (2:1) showed that CPT and CUR were evenly distributed within individual fibers of these meshes. Drug release experiments revealed that both types of drugs could be released from fibrous meshes simultaneously and sustainably. Importantly, these meshes exhibited strong in vitro anti-colon cancer activities, compared with the control meshes without drugs. Moreover, the combination index values of the PF127-CPT/CUR-meshes (CPT/CUR weight ratio = 5:1, 3:1, or 2:1) were <0.5 after incubation for respective 24 and 36 h, indicating the synergistic anti-colon cancer effects of CPT and CUR in fibrous meshes. Collectively, these results demonstrate that PF127-CPT/CUR-meshes can be developed as an efficient implantable system for effective synergistic treatment of colon cancer.
- 1 June 2019
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 99, 591-598
Modulation of drug release by decoration with Pluronic F127 to improve anti-colon cancer activity of electrospun fibrous meshes
- 1 June 2019
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 99, 591-598
Modulation of drug release by decoration with Pluronic F127 to improve anti-colon cancer activity of electrospun fibrous meshes
- 21 March 2019
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 19 (4) , 304-311
Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles
Background: Oral administrations of microparticles (MPs) and nanoparticles (NPs) have been widely employed as therapeutic approaches for the treatment of ulcerative colitis (UC). However, no previous study has comparatively investigated the therapeutic efficacies of MPs and NPs. Methods: In this study, curcumin (CUR)-loaded MPs (CUR-MPs) and CUR-loaded NPs (CUR-NPs) were prepared using a single water-in-oil emulsion solvent evaporation technique. Their therapeutic outcomes against UC were further comparatively studied. Results: The resultant spherical MPs and NPs exhibited slightly negative zeta-potential with average particle diameters of approximately 1.7 µm and 270 nm, respectively. It was found that NPs exhibited a much higher CUR release rate than MPs within the same period of investigation. In vivo experiments demonstrated that oral administration of CUR-MPs and CUR-NPs reduced the symptoms of inflammation in a UC mouse model induced by dextran sulfate sodium. Importantly, CUR-NPs showed much better therapeutic outcomes in alleviating UC compared with CUR-MPs. Conclusion: NPs can improve the anti-inflammatory activity of CUR by enhancing the drug release and cellular uptake efficiency, in comparison with MPs. Thus, they could be exploited as a promising oral drug delivery system for effective UC treatment.
- 21 March 2019
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 19 (4) , 304-311
Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles
Background: Oral administrations of microparticles (MPs) and nanoparticles (NPs) have been widely employed as therapeutic approaches for the treatment of ulcerative colitis (UC). However, no previous study has comparatively investigated the therapeutic efficacies of MPs and NPs. Methods: In this study, curcumin (CUR)-loaded MPs (CUR-MPs) and CUR-loaded NPs (CUR-NPs) were prepared using a single water-in-oil emulsion solvent evaporation technique. Their therapeutic outcomes against UC were further comparatively studied. Results: The resultant spherical MPs and NPs exhibited slightly negative zeta-potential with average particle diameters of approximately 1.7 µm and 270 nm, respectively. It was found that NPs exhibited a much higher CUR release rate than MPs within the same period of investigation. In vivo experiments demonstrated that oral administration of CUR-MPs and CUR-NPs reduced the symptoms of inflammation in a UC mouse model induced by dextran sulfate sodium. Importantly, CUR-NPs showed much better therapeutic outcomes in alleviating UC compared with CUR-MPs. Conclusion: NPs can improve the anti-inflammatory activity of CUR by enhancing the drug release and cellular uptake efficiency, in comparison with MPs. Thus, they could be exploited as a promising oral drug delivery system for effective UC treatment.
- 15 April 2018
- Published by Wiley in Macromolecular Materials and Engineering
- Vol. 303 (5)
Knitted Silk Fibroin‐Reinforced Bead‐on‐String Electrospun Fibers for Sustained Drug Delivery Against Colon Cancer
Bead‐on‐string electrospun fibers containing camptothecin (CPT) are fabricated on the surface of knitted silk fibroin (SF) meshes. Microscopic characterization reveals that the bead‐on‐string structure is prepared successfully and CPT is mainly located within the beaded structure. Interestingly, the CPT‐loaded beaded SF mesh (CPT‐SF mesh) has excellent mechanical properties. More importantly, it is able to perform a sustained CPT release without burst release. In vitro cytotoxicity tests further indicate that the CPT‐SF mesh shows much stronger anticolon cancer activity in comparison with SF meshes and beaded SF meshes. Hence, the CPT‐SF mesh has great potential as a promising local drug delivery system for colon cancer treatment.
- 15 April 2018
- Published by Wiley in Macromolecular Materials and Engineering
- Vol. 303 (5)
Knitted Silk Fibroin‐Reinforced Bead‐on‐String Electrospun Fibers for Sustained Drug Delivery Against Colon Cancer
Bead‐on‐string electrospun fibers containing camptothecin (CPT) are fabricated on the surface of knitted silk fibroin (SF) meshes. Microscopic characterization reveals that the bead‐on‐string structure is prepared successfully and CPT is mainly located within the beaded structure. Interestingly, the CPT‐loaded beaded SF mesh (CPT‐SF mesh) has excellent mechanical properties. More importantly, it is able to perform a sustained CPT release without burst release. In vitro cytotoxicity tests further indicate that the CPT‐SF mesh shows much stronger anticolon cancer activity in comparison with SF meshes and beaded SF meshes. Hence, the CPT‐SF mesh has great potential as a promising local drug delivery system for colon cancer treatment.
- 1 March 2017
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 490, 520-528
Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages
- 1 March 2017
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 490, 520-528
Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages
- 1 July 2016
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 143, 186-193
Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages
- 1 July 2016
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 143, 186-193
Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages